248. SYSTEMIC INFLAMMATORY MARKERS AS PROGNOSTIC FACTORS IN ESOPHAGEAL CANCER: A MEXICAN PERSPECTIVE

Abstract Background Esophageal cancer (EC) represents the eighth most commonly diagnosed cancer, and sixth cause of cancer-related deaths worldwide. Several studies have demonstrated an association between systemic inflammation, anti-cancer immunity, poor oncological outcomes in patients with EC. Biomarkers including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte (LMR), platelet-to-lymphocyte (PLR) may reflect balance pro-cancer inflammation immune response prognostic implications Mexican esophageal patients. Methods A retrospective review a prospectively collected database all EC from 2011–2022 was performed. Baseline pre-treatment NLR, LMR PLR collected. The date last follow-up or death ascertained medical records. ROC curves were used to calculate cut-off values for NLR PLR, while median-value LMR. Serum albumin <3.5 g/dL considered malnutrition. Kaplan–Meier (univariate) Cox regression (multivariate) performed evaluate survival against factors. Results 498 included during study period, 80.1% men 19.9% women, median age 60 (±12.2) years old. Adenocarcinoma (49.8%) common histological subtype, followed by squamous cell carcinoma (31.7%). Clinical stage included: I (3%), IIA-B (11.8%), III (37.6%), IVA (2.6%), IVB (44.2%). Neoadjuvant chemoradiotherapy predominant initial therapy (50.4%), chemotherapy (41.7%). revealed following value: 2.92 174 IPL, 3.5 In univariate analysis, four factors significant overall (NLR, LMR, albumin) (Table 1), multivariate analysis only remained independent 2). Conclusion our population, low high can be markers cancer. These pretreatment biomarkers serve identify good factors, contributing improved consent process therapeutic decision making. Further research should focus on more accurate prognostication.